Amsterdam, The Netherlands, June 5, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product […]
Amsterdam, The Netherlands, May 16, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product […]
16 May 2018
Amsterdam, The Netherlands, April 23, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product […]
23 April 2018
Significantly strengthened cash position; raised over EUR 60 million in equity and debt (gross, including raise in March 2018) Filed Marketing Authorization Application with the European Medicines Agency for ATIR101 […]
13 April 2018
Amsterdam, The Netherlands, March 29, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate […]
29 March 2018
Responses submitted to EMA Day 120 list of questions Amsterdam, The Netherlands, March 28, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical […]
28 March 2018
Amsterdam, The Netherlands, March 14, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product […]
15 March 2018
12 March 2018
Results from the single dose 1-year follow up consistent with prior Phase II study Data supports already submitted marketing authorization application Amsterdam-Duivendrecht, The Netherlands, January 31, 2018 – Kiadis Pharma […]
31 January 2018